Prostate-Specific Membrane Antigen-Targeted Therapy in Prostate Cancer: History, Combination Therapies, Trials, and Future Perspective
Open accessThe DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Abstract
In the last decades, the development of PET/CT radiopharmaceuticals, targeting the Prostate-Specific Membrane Antigen (PSMA), changed the management of prostate cancer (PCa) patients thanks to its higher diagnostic accuracy in comparison with conventional imaging both in staging and in recurrence. Alongside molecular imaging, PSMA was studied as a therapeutic agent targeted with various isotopes. In 2021, results from the VISION trial led to the Food and Drug Administration (FDA) approval of [177Lu]Lu-PSMA-617 as a novel therapy for metastatic castration-resistant prostate cancer (mCRPC) and set the basis for a radical change in the future perspectives of PCa treatment and the history of Nuclear Medicine. Despite these promising results, primary resistance in patients treated with single-agent [177Lu]Lu-PSMA-617 remains a real issue. Emerging trials are investigating the use of [177Lu]Lu-PSMA-617 in combination with other PCa therapies in order to cover the multiple oncologic resistance pathways and to overcome tumor heterogeneity. In this review, our aim is to retrace the history of PSMA-targeted therapy from the first preclinical studies to its future applications in PCa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Combining PSMA-targeted RLT with other available therapies such as ARPIs, chemotherapy, immunotherapy, and targeted therapy can enhance PSMA expression and improve therapeutic outcomes”
From PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future (2025) · cites this paper as [37]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 1×
“…combined with chemotherapy [4,5], with a novel androgen receptor pathway inhibitor (ARPI) (e.g., abiraterone, enzalutamide, or apalutamide) [6–8], or even used inside a triplet regimen treatment along with the concomitant administration of ARPI (abiraterone or darolutamide) plus docetaxel [9,10].”
BackgroundSipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 2×
“In a multicenter phase III trial, Sipuleucel-T, an autologous active cellular immunotherapy, prolonged OS among asymptomatic or minimally symptomatic mCRPC patients (predominantly before chemotherapy) compared with placebo [18].”
BackgroundMethodIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Petrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408 · cited 1×
“In a phase III trial, [ 223 Ra]Ra-dichloride, an α emitter that selectively targets bone metastases, improved over-all survival (OS) compared with placebo, in addition to the best standard of care, in men with castration-resistant PCa and bone metastases [17].”
Backgroundde Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028 · cited 1×
“In 2004, docetaxel demonstrated to prolong survival in two phase III trials [11,12], while abiraterone and enzalutamide are life-prolonging treatments in mCRPC patients when used both as first-line therapy and post-docetaxel [13,14].”
BackgroundChemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney, C. J., Chen, Y.-H., Carducci, M., Liu, G., Jarrard, D. F., Eisenberger, M., Wong, Y.-N., Hahn, N., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,896
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107322 · Cited by 2,864 · cited 4×
“The VISION trial evaluated the effects of [ 177 Lu]Lu-PSMA-617 in PSMA-positive mCRPC patients [28].”
MethodResultInfluential
Research works printed but not linked: 2
- (2023, January 9). EAU Guidelines. Proceedings of the Presented at the EAU Annual Congress, Milan, Italy.
- Sathekge, 2023, AcTION: A phase 1 study of [225Ac]Ac-PSMA-617 in men with PSMA-positive prostate cancer with or without prior [177Lu]Lu-PSMA-617 radioligand therapy, In: Annual Congress of the European Association of Nuclear Medicine, 3–13 September 2023, Vienna, Austria, J. Nucl. Med., 50, S152
Cited by
Bogdanović, B., Fagret, D., Ghezzi, C., & Montemagno, C. (2024) · Pharmaceuticals · doi:10.3390/ph17111556 · Cited by 55
Zahednezhad, F., Allahyari, S., Sarfraz, M., Zakeri‐Milani, P., Feyzizadeh, M., & Valizadeh, H. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2394611 · Cited by 23
Watabe, T., Kaneda‐Nakashima, K., Kadonaga, Y., Ooe, K., Sampunta, T., Hirose, N., Yin, X., Haba, H., Kon, Y., Toyoshima, A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115667 · Cited by 22
PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future
Ayzman, A., Pachynski, R. K., & Reimers, M. A. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01317-5 · Cited by 18
“Combining PSMA-targeted RLT with other available therapies such as ARPIs, chemotherapy, immunotherapy, and targeted therapy can enhance PSMA expression and improve therapeutic outcomes [37].”
Development of PSMA-Targeted Alpha Therapy Using [211At]PSMA-5
Watabe, T., Naka, S., Shirakami, Y., Kaneda‐Nakashima, K., Murakami, M., Toyoshima, A., Cardinale, J., & Giesel, F. L. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.09.005 · Cited by 10
Metadata
- Authors
- Mattana, F., Muraglia, L., Barone, A., Colandrea, M., Saker Diffalah, Y., Provera, S., Cascio, A. S., Omodeo Salè, E., & Ceci, F.
- Affiliations
- European Institute of Oncology (IT)
- Division of Nuclear Medicine, Humanitas IRCCS, 20141 Milan, Italy
- Division of Nuclear Medicine, Hospital Clínico Universitario Lozano Blesa, 50009 Zaragoza, Spain
- Division of Pharmacy, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy
- University of Milan (IT)
- Corresponding author
- Mattana, Francesco
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2024-04-25
- Volume
- 16
- Issue
- 9
- Pages
- 1643
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC11083597
- OpenAlex
- W4395453742
- Cited by
- 16
- References
- 61
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 6
- FWCI
- 1.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- prostate-specific membrane antigen, PSMA-targeted therapy, prostate cancer, metastatic castration-resistant prostate cancer, 177Lu-PSMA-617, radiopharmaceuticals, PET/CT imaging, VISION trial, combination therapy, primary resistance, tumor heterogeneity, history of nuclear medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prostate-Specific Membrane Antigen-Targeted Therapy in Prostate Cancer: History, Combination Therapies, Trials, and Future Perspective. https://app.cochat.ai/papers/10.3390/cancers16091643
- The paper
- Mattana, F., Muraglia, L., Barone, A., Colandrea, M., Saker Diffalah, Y., Provera, S., Cascio, A. S., Omodeo Salè, E., & Ceci, F. (2024). Prostate-Specific Membrane Antigen-Targeted Therapy in Prostate Cancer: History, Combination Therapies, Trials, and Future Perspective. Cancers. https://doi.org/10.3390/cancers16091643
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.